Sodium‐glucose co‐transporter protein 2 inhibitors for long-term kidney function preservation in type 2 diabetes with chronic kidney disease: a meta-analysis of rates of progression to end-stage renal disease
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20243771Keywords:
SGLT2 inhibitors, CKD, T2DM, ESRD, Meta-analysis, Randomized controlled trialsAbstract
Chronic kidney disease (CKD) is a major complication of type 2 diabetes mellitus (T2DM) and a leading cause of end-stage renal disease (ESRD). Sodium-glucose co-transporter 2 (SGLT2) inhibitors have demonstrated renoprotective effects in clinical trials, but their precise impact on ESRD risk remains to be comprehensively quantified. This study aimed to evaluate the effectiveness of SGLT2 inhibitors in reducing ESRD risk in T2DM patients with CKD by synthesizing evidence from randomized controlled trials. A meta-analysis was conducted using data from eight randomized controlled trials involving 28,253 participants. Studies comparing SGLT2 inhibitors with placebo in T2DM patients with CKD were included. The primary outcome was the risk of ESRD, reported as a pooled risk ratio (RR) with 95% confidence intervals (CIs). Heterogeneity was assessed using the I² statistic. The pooled analysis demonstrated a significant reduction in ESRD risk with SGLT2 inhibitors compared to placebo (RR, 0.73; 95% CI, 0.66–0.82), indicating a 27% risk reduction. Heterogeneity was low (I²=0%; p=0.50), confirming consistency across trials. Subgroup analyses showed similar reductions across different CKD stages and follow-up durations. In conclusion, SGLT2 inhibitors significantly reduce the risk of ESRD in T2DM patients with CKD, highlighting their renoprotective potential. These findings support the integration of SGLT2 inhibitors into standard care for high-risk populations to delay CKD progression and prevent ESRD.
Metrics
References
Nanda M, Sharma R, Mubarik S, Aashima A, Zhang K. Type-2 diabetes mellitus (T2DM): spatial-temporal patterns of incidence, mortality and attributable risk factors from 1990 to 2019 among 21 world regions. Endocrine. 2022;77(3):444-54.
Liu B, Li L, Cui H, Zhao Q, Chen S. Analysis of the global burden of CKD-T2DM in young and middle-aged adults in 204 countries and territories from 2000 to 2019: A systematic study of the global burden of disease in 2019. Diabetes Res Clin Pract. 2024;217:111884.
Fenta ET, Eshetu HB, Kebede N, Bogale EK, Zewdie A, Kassie TD, et al. Prevalence and predictors of chronic kidney disease among type 2 diabetic patients worldwide, systematic review and meta-analysis. Diabetol Metab Syndrome. 2023;15(1):245.
Wheeler DC, James J, Patel D, Viljoen A, Ali A, Evans M, et al. SGLT2 inhibitors: slowing of chronic kidney disease progression in type 2 diabetes. Diabetes Therapy. 2020;11:2757-74.
DeFronzo RA, Reeves WB, Awad AS. Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. Nat Rev Nephrol. 2021;17(5):319-34.
Wright EM. SGLT2 inhibitors: physiology and pharmacology. Kidney360. 2021;2(12):2027-37.
Oe Y, Vallon V. The pathophysiological basis of diabetic kidney protection by inhibition of SGLT2 and SGLT1. Kidney Dialysis. 2022;2(2):349-68.
Davidson JA. SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence. Postgrad Med. 2019;131(4):251-60.
Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020;17(12):761-72.
Seidu S, Kunutsor SK, Cos X, Gillani S, Khunti K. SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: a systematic review and meta-analysis. Prim Care Diabetes. 2018;12(3):265-83.
Kelly MS, Lewis J, Huntsberry AM, Dea L, Portillo I. Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease. Postgrad Med. 2019;131(1):31-42.
Spiazzi BF, Piccoli GF, Wayerbacher LF, Lubianca JP, Scalco BG, Scheffler MH, et al. SGLT2 inhibitors and kidney outcomes across the spectrum of kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2024;10:2215.
McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZ, Dagogo-Jack S, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021;6(2):148-58.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;29:372.
Review Manager (RevMan). Version 5.4. The Cochrane Collaboration. Available at: revman.cochrane.org. Accessed on 12 August 2024.
Allegretti AS, Zhang W, Zhou W, Thurber TK, Rigby SP, Bowman-Stroud C, et al. Safety and effectiveness of bexagliflozin in patients with type 2 diabetes mellitus and stage 3a/3b CKD. Am J Kidney Dis. 2019;74(3):328-37.
Fioretto P, Del Prato S, Buse JB, Goldenberg R, Giorgino F, Reyner D, et al, DERIVE Study Investigators. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study. Diabetes Obesity Metabolism. 2018;20(11):2532-40.
Herrington WG, Staplin N, Agrawal N, Wanner C, Green JB, Hauske SJ, et al. Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2024;25:10-56.
Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85(4):962-71.
Neal B, Perkovic V, Mahaffey KW, De Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644-57.
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJ, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295-306.
Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323-34.
Wheeler DC, Stefánsson BV, Jongs N, Chertow GM, Greene T, Hou FF, et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(1):22-31.
Geng S, Li Y, Ge J, Liu Y, Li Q, Chen X, et al. Nephroprotective effect of SGLT2 inhibitors in elderly patients with type 2 diabetes mellitus and hypertension: a real-world population-based cohort study. Postgrad Med. 2024;136(8):855-63.
Garofalo C, Borrelli S, Liberti ME, Andreucci M, Conte G, Minutolo R, et al. SGLT2 inhibitors: nephroprotective efficacy and side effects. Medicina. 2019;55(6):268.
Yaribeygi H, Simental-Mendía LE, Banach M, Bo S, Sahebkar A. The major molecular mechanisms mediating the renoprotective effects of SGLT2 inhibitors: An update. Biomed Pharmacotherapy. 2019;120:109526.
Neuen BL, Young T, Heerspink HJ, Neal B, Perkovic V, Billot L, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7(11):845-54.
Scheen AJ, Delanaye P. Understanding the protective effects of SGLT2 inhibitors in type 2 diabetes patients with chronic kidney disease. Exp Rev Endocrinol Metabolism. 2022;17(1):35-46.
Giorgino F, Vora J, Fenici P, Solini A. Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk. Cardiovasc Diabetol. 2020;19:1-9.
Downloads
Published
How to Cite
Issue
Section
